Specific price situation of fostatinib/fotantinib

Fostamatinib is an oral small molecule tyrosine kinase inhibitor developed by Rigel Pharmaceuticals in the United States, with the trade name Tavalisse. This drug mainly regulates abnormal signaling pathways of the immune system by inhibiting the activity of spleen tyrosine kinase (Syk). It is currently one of the few innovative targeted drugs for immune thrombocytopenia (ITP). ITP is a disease caused by abnormalities in the immune system. The patient's body produces antibodies against its own platelets, causing the platelets to be excessively destroyed by the spleen, leading to symptoms such as bleeding tendencies, subcutaneous ecchymoses, or gum bleeding. The mechanism of fotantinib is to help patients restore the number of platelets and improve bleeding symptoms by blocking the signaling pathway by which macrophages phagocytose platelets.

Currently, the original drug of fotantinib has been approved for marketing in the United States, Canada, Europe and other places. It is mainly used for adult ITP patients who have failed to respond to traditional glucocorticoids, intravenous immunoglobulin (IVIG) or splenectomy. The drug is taken as an oral formulation and is usually taken twice daily to maintain stable platelet levels. Because the drug has good targeting and controllable side effect characteristics, it is considered a new direction in the treatment of chronic ITP.

In terms of price, the original drug of fotantinib has not yet been officially launched in mainland China, so there is no official price and medical insurance reimbursement policy in the domestic market. Currently in the international market, the common specifications of the German version of the original drug include 100 mg 60 tablets and 150 mg 60 tablets. The price per box is about 20,000 to 40,000 yuan, and the specific amount depends on the exchange rate and regional taxes and fees. Since there is no generic version of Fotantinib, patients who need medication mainly rely on regular overseas pharmacies or global drug supply channels. Despite its higher price, its unique targeting mechanism and potential benefits for patients with refractory ITP make it an innovative treatment option with great clinical value.

Reference materials:https://go.drugbank.com/drugs/DB12010